Is Pepcid Good for Diarrhea or Can It Cause It?

Pepcid (famotidine) is not designed to treat diarrhea, and it rarely causes it either. Its job is to reduce stomach acid, which means it sits in a different pharmacological lane from antidiarrheal drugs entirely. But the relationship between Pepcid and diarrhea is more interesting than a simple “no and no,” because acid suppression has downstream effects on gut bacteria, intestinal fluid balance, and motility that can nudge things in either direction depending on the circumstances.

What Pepcid Actually Does

Famotidine belongs to a class of drugs called H2-receptor antagonists, or H2 blockers. Histamine, the same chemical involved in allergic reactions, also plays a role in telling your stomach’s acid-producing cells to ramp up. Famotidine blocks the histamine receptors on those cells, dialing acid production down. On a molecular level, it is considerably more potent than ranitidine (the former active ingredient in Zantac), blocking acid output at much lower concentrations.¹ People use it for heartburn, gastroesophageal reflux, and peptic ulcers. Nothing about that mechanism directly targets diarrhea or constipation.

When Pepcid Can Actually Help with Diarrhea

There are a few specific situations where reducing stomach acid with famotidine can improve loose stools, even though Pepcid is not an antidiarrheal drug.

The most clear-cut scenario involves conditions where the body massively overproduces stomach acid. Zollinger-Ellison syndrome, a rare condition driven by a gastrin-secreting tumor, causes the stomach to flood the upper intestine with acid. That acid overwhelms the intestine’s ability to absorb water and nutrients, leading to chronic watery diarrhea along with ulcers and reflux.² Blocking acid production with famotidine (sometimes at very high doses) can reduce that diarrhea because you are treating its cause. Proton pump inhibitors are more commonly used for this today, but famotidine has a long track record in managing the condition and is generally well tolerated even at elevated doses.²

A second, more common situation involves people switching from a stronger acid suppressor (a proton pump inhibitor like omeprazole) to famotidine. Long-term PPI use can alter the bacterial populations in the small intestine, sometimes leading to a condition called small intestinal bacterial overgrowth (SIBO), which causes bloating, gas, and diarrhea. In at least one documented case, switching from a PPI to an H2 blocker like famotidine resolved both the patient’s symptoms and abnormal lab results.³ The reasoning is that famotidine suppresses acid less aggressively than PPIs, preserving more of the stomach’s natural antimicrobial barrier. So if your diarrhea is a downstream consequence of heavy acid suppression, stepping down to Pepcid could help, though this is a decision to make with a doctor rather than on your own.

Does Pepcid Cause Diarrhea as a Side Effect?

Diarrhea appears on the official side-effect list for famotidine, but it is not common. In clinical studies and post-marketing surveillance, famotidine has been described as generally well tolerated across a range of patient populations, including people with kidney or liver problems and those taking high doses for acid hypersecretion syndromes. The most frequently reported side effects tend to be headache and dizziness, not gastrointestinal complaints. If you do experience loose stools after starting Pepcid, the drug itself is rarely the culprit, but there is a subtler possibility worth knowing about.

The Inactive Ingredient Problem

Sometimes what looks like a drug side effect is actually a reaction to what the pill is made of besides the active ingredient. Many chewable and liquid formulations of over-the-counter medications, including some versions of Pepcid, contain sugar alcohols like sorbitol and mannitol as sweeteners. These substances are poorly absorbed in the gut, and because they pull water into the intestine through osmotic pressure, they can cause bloating, gas, and diarrhea, especially in sensitive individuals or children.⁴ If you notice that chewable Pepcid seems to upset your stomach while swallowed tablets do not, the excipients are a likely explanation. Checking the inactive ingredient list on the box can save you from blaming the drug for something the sweetener is doing.

Histamine Receptors in the Intestine

The story gets more interesting when you consider that H2 receptors are not limited to the stomach. Histamine receptors show up throughout the intestinal wall, including in the nerve networks that coordinate gut movement and secretion. Research on human intestinal tissue has found that histamine activates neurons in the gut’s nerve plexus through multiple receptor types, including H2 receptors.⁵ These neurons help regulate how much fluid the intestinal lining secretes.

Animal studies have shown that histamine acting on H2 receptors in the colon triggers chloride secretion, which is one of the main drivers of water movement into the intestinal space.⁶ In theory, blocking those receptors with famotidine could reduce that fluid secretion and have a mild anti-secretory effect. This is probably not strong enough to treat full-blown diarrhea in most cases, and it is not why doctors prescribe Pepcid, but it does mean the drug has at least a plausible mechanism for slightly reducing intestinal water content. The clinical significance of this effect in humans taking standard Pepcid doses is unclear and understudied.

What Pepcid Does to Gastric Emptying

How quickly your stomach empties its contents into the small intestine affects stool consistency. If food moves through too fast, the intestine has less time to absorb water, and you end up with looser stools. So a drug that changes gastric emptying speed could theoretically influence diarrhea in either direction.

The evidence on famotidine and gastric emptying is mixed. One study measuring stomach contractions and emptying after a meal found that famotidine, along with ranitidine and omeprazole, slowed gastric emptying while increasing the strength of stomach contractions.⁷ That would suggest Pepcid might modestly slow things down after eating. But a separate crossover study in healthy volunteers found that famotidine had no significant effect on gastric emptying time.⁸ The discrepancy likely comes down to differences in how gastric emptying was measured and under what conditions. The practical takeaway is that any effect Pepcid has on transit speed is small enough to go either way in studies, so it is unlikely to meaningfully change your bowel habits through this mechanism alone.

Pepcid vs. PPIs and Infection-Related Diarrhea

One of the most important things to know about acid-suppressing drugs and diarrhea is the difference between H2 blockers like Pepcid and proton pump inhibitors like omeprazole or lansoprazole. PPIs suppress acid far more powerfully than H2 blockers, and that deeper suppression comes with a measurable increase in the risk of bacterial gut infections, many of which cause diarrhea.

Stomach acid is one of your body’s first defenses against swallowed bacteria. When acid levels drop, bacteria that would normally be killed in the stomach can survive and colonize the intestine. A large study found that current PPI use roughly tripled the risk of bacterial gastroenteritis compared to nonuse. H2 blocker use, by contrast, showed no increased risk at all.⁹ Neither cimetidine nor ranitidine (both H2 blockers, like famotidine) was associated with a higher rate of bacterial gut infections in that analysis.

A separate population-based cohort study spanning over a decade confirmed this pattern. People taking PPIs had a significantly higher rate of culture-positive diarrhea compared to matched controls, while the increase associated with H2 blockers was much smaller.¹⁰ The gap matters because it suggests that the level of acid suppression, not acid suppression per se, is what drives infection risk. Famotidine leaves more residual acid in the stomach than a PPI does, and that remaining acid still does meaningful antimicrobial work.

The C. difficile Question

Clostridioides difficile infection (commonly called C. diff) is a particularly dangerous cause of diarrhea, especially in hospitalized and elderly patients. It has become closely associated with acid-suppressing drugs in the medical literature, but the risk is not equal across drug classes.

In a large study of ICU patients comparing H2 blockers to PPIs, C. diff infection occurred in about 2.2% of the H2 blocker group versus 3.8% of the PPI group. After adjusting for other risk factors, PPI use was associated with about 29% higher odds of C. diff infection compared to H2 blockers.¹¹ This has led some hospitals to prefer H2 blockers for stress ulcer prevention in patients who do not specifically need a PPI.

The picture is a bit more complicated for outpatient use. A 15-year hospital cohort study found that both PPIs and H2 blockers were associated with a higher risk of C. diff compared to people not taking either drug, with the hazard ratios being fairly similar between the two classes.¹² A pharmacovigilance analysis of adverse-event reports also found a safety signal linking famotidine to pneumonia but, interestingly, did not generate a signal for C. diff colitis specifically.¹³ So while H2 blockers are not entirely free of gut-infection concerns, they carry a consistently lower risk than PPIs do.

For someone already taking a PPI and experiencing recurrent diarrhea or recurrent C. diff infections, stepping down to famotidine is a strategy some gastroenterologists consider. It provides some acid suppression while restoring more of the stomach’s natural defense against pathogenic bacteria.

Who Should Be Cautious

Famotidine is cleared through the kidneys. If your kidneys are not working well, the drug stays in your system longer, which can amplify both its intended effects and any side effects. People with significant kidney impairment typically need a lower dose. That said, famotidine has been studied in patients with renal dysfunction and has been found to be generally well tolerated even in those populations.

Older adults deserve particular attention, both because kidney function tends to decline with age and because this group is more vulnerable to C. diff and other gut infections. The evidence we reviewed suggests that famotidine carries a lower infection risk than PPIs, but “lower” does not mean “zero.” If you are over 65 and taking Pepcid daily, the safest approach is to use the lowest effective dose for the shortest time needed, and to make sure your doctor knows about it. This is especially true if you are also taking antibiotics, which independently raise the risk of C. diff.

For otherwise healthy adults using over-the-counter Pepcid occasionally for heartburn, the risk of diarrhea from the drug itself is genuinely low. You are far more likely to get diarrhea from a stomach bug, a dietary trigger, or the sorbitol in a chewable tablet than from famotidine’s pharmacological action on your gut.

Why People Confuse Pepcid with Antidiarrheals

Part of the confusion around Pepcid and diarrhea comes from the pharmacy aisle itself. Pepcid sits on the same shelf as Pepto-Bismol and Imodium, all filed under “digestive health.” Consumers who grab the wrong pink box or who remember that “some stomach medicine helps diarrhea” can end up reaching for an acid reducer when they need an antidiarrheal, or vice versa. Pepto-Bismol (bismuth subsalicylate) actually does treat diarrhea through antibacterial and anti-secretory mechanisms. Imodium (loperamide) slows intestinal motility directly. Famotidine does neither of those things as a primary effect.

There is also a common assumption that because acid-related conditions sometimes cause diarrhea (as in Zollinger-Ellison syndrome or severe reflux with bile acid spillover), any acid reducer should help any diarrhea. That logic breaks down because most diarrhea has nothing to do with excess stomach acid. Viral gastroenteritis, food intolerances, inflammatory bowel disease, irritable bowel syndrome, medication side effects, and dozens of other causes all produce diarrhea through mechanisms that famotidine does not touch.

Famotidine and Gut Microbiome Shifts

A newer area of research involves what acid-suppressing drugs do to the overall community of bacteria living in your gut. PPIs have received the most attention here, with studies linking long-term use to measurable shifts in the types of bacteria populating the small and large intestine. These shifts can contribute to SIBO and to the kinds of dysbiosis that predispose people to diarrheal illness.

H2 blockers have been studied less extensively in this context, but the available evidence suggests their impact on the microbiome is milder. The case report of a patient whose SIBO resolved after switching from a PPI to an H2 blocker is one illustration of this.³ The logic is straightforward: less acid suppression means more surviving stomach acid, which means fewer bacteria making it past the stomach into the small intestine. This does not mean famotidine is entirely neutral toward the microbiome, but the disruption appears to be substantially less than what PPIs produce, which tracks with the infection-risk data discussed earlier.

For people who need long-term acid suppression but are worried about gut health, this distinction between drug classes is worth discussing with a healthcare provider. Famotidine may not suppress acid as completely as a PPI, but for milder reflux or maintenance therapy, that weaker suppression can be a feature rather than a limitation.